Published in AIDS Res Hum Retroviruses on December 01, 2009
HIV coreceptor tropism in paired plasma, peripheral blood mononuclear cell, and cerebrospinal fluid isolates from antiretroviral-naïve subjects. J Clin Microbiol (2011) 0.94
How much do antiretroviral drugs penetrate into the central nervous system? J Med Life (2011) 0.91
Reduced Baseline Sensitivity to Maraviroc Inhibition Among R5 HIV-1 Isolates From Individuals With Severe Immunodeficiency. J Acquir Immune Defic Syndr (2016) 0.76
Frequency and Env determinants of HIV-1 subtype C strains from antiretroviral therapy-naive subjects that display incomplete inhibition by maraviroc. Retrovirology (2016) 0.75
HIV-1 entry cofactor: functional cDNA cloning of a seven-transmembrane, G protein-coupled receptor. Science (1996) 26.19
HIV-1 entry into CD4+ cells is mediated by the chemokine receptor CC-CKR-5. Nature (1996) 20.59
Updated research nosology for HIV-associated neurocognitive disorders. Neurology (2007) 16.18
Detection of AIDS virus in macrophages in brain tissue from AIDS patients with encephalopathy. Science (1986) 11.74
Prognostic value of HIV-1 syncytium-inducing phenotype for rate of CD4+ cell depletion and progression to AIDS. Ann Intern Med (1993) 7.21
Validation of the CNS Penetration-Effectiveness rank for quantifying antiretroviral penetration into the central nervous system. Arch Neurol (2008) 6.91
The brain in AIDS: central nervous system HIV-1 infection and AIDS dementia complex. Science (1988) 6.51
CCR3 and CCR5 are co-receptors for HIV-1 infection of microglia. Nature (1997) 5.45
Reservoirs for HIV-1: mechanisms for viral persistence in the presence of antiviral immune responses and antiretroviral therapy. Annu Rev Immunol (2000) 4.46
A small-molecule, nonpeptide CCR5 antagonist with highly potent and selective anti-HIV-1 activity. Proc Natl Acad Sci U S A (1999) 4.46
Development and characterization of a novel single-cycle recombinant-virus assay to determine human immunodeficiency virus type 1 coreceptor tropism. Antimicrob Agents Chemother (2006) 4.14
HIV-1 V3 domain variation in brain and spleen of children with AIDS: tissue-specific evolution within host-determined quasispecies. Virology (1991) 3.33
A binding pocket for a small molecule inhibitor of HIV-1 entry within the transmembrane helices of CCR5. Proc Natl Acad Sci U S A (2000) 3.10
Relationship between human immunodeficiency virus-associated dementia and viral load in cerebrospinal fluid and brain. Ann Neurol (1997) 2.92
Macrophage tropism of human immunodeficiency virus type 1 isolates from brain and lymphoid tissues predicts neurotropism independent of coreceptor specificity. J Virol (2001) 2.79
Specific tropism of HIV-1 for microglial cells in primary human brain cultures. Science (1990) 2.74
In vivo compartmentalization of human immunodeficiency virus: evidence from the examination of pol sequences from autopsy tissues. J Virol (1997) 2.71
Simple, sensitive, and specific detection of human immunodeficiency virus type 1 in clinical specimens by polymerase chain reaction with nested primers. J Clin Microbiol (1990) 2.71
Neuronal apoptosis induced by HIV-1 gp120 and the chemokine SDF-1 alpha is mediated by the chemokine receptor CXCR4. Curr Biol (1998) 2.21
Genetic and functional analysis of full-length human immunodeficiency virus type 1 env genes derived from brain and blood of patients with AIDS. J Virol (2003) 2.07
Human immunodeficiency virus type 1 T-lymphotropic strains enter macrophages via a CD4- and CXCR4-mediated pathway: replication is restricted at a postentry level. J Virol (1998) 2.00
Immune activation of the central nervous system is still present after >4 years of effective highly active antiretroviral therapy. J Infect Dis (2007) 1.92
MT-2 cell tropism as prognostic marker for disease progression in human immunodeficiency virus type 1 infection. J Clin Microbiol (1994) 1.72
Microglia express CCR5, CXCR4, and CCR3, but of these, CCR5 is the principal coreceptor for human immunodeficiency virus type 1 dementia isolates. J Virol (1999) 1.60
Sensitivity to inhibition by beta-chemokines correlates with biological phenotypes of primary HIV-1 isolates. Proc Natl Acad Sci U S A (1996) 1.54
Cerebrospinal fluid viral load, intrathecal immunoactivation, and cerebrospinal fluid monocytic cell count in HIV-1 infection. J Acquir Immune Defic Syndr (1999) 1.53
Persistent intrathecal immune activation in HIV-1-infected individuals on antiretroviral therapy. J Acquir Immune Defic Syndr (2008) 1.47
Asn 362 in gp120 contributes to enhanced fusogenicity by CCR5-restricted HIV-1 envelope glycoprotein variants from patients with AIDS. Retrovirology (2007) 1.41
Elevated cerebrospinal fluid neurofilament light protein concentrations predict the development of AIDS dementia complex. J Infect Dis (2007) 1.36
Improvement of the gene splicing overlap (SOE) method. Biotechniques (1995) 1.32
Chemokine receptor utilization by human immunodeficiency virus type 1 isolates that replicate in microglia. J Virol (1998) 1.30
Defining and evaluating HIV-related neurodegenerative disease and its treatment targets: a combinatorial approach to use of cerebrospinal fluid molecular biomarkers. J Neuroimmune Pharmacol (2006) 1.24
CSF neurofilament protein (NFL) -- a marker of active HIV-related neurodegeneration. J Neurol (2007) 1.22
Human immunodeficiency virus neurotropism: an analysis of viral replication and cytopathicity for divergent strains in monocytes and microglia. J Virol (1998) 1.22
Chemokine receptors and human immunodeficiency virus infection. Front Biosci (1998) 1.18
Coevolution of RANTES sensitivity and mode of CCR5 receptor use by human immunodeficiency virus type 1 of the R5 phenotype. J Virol (2004) 1.17
Selection of human immunodeficiency virus type 1 R5 variants with augmented replicative capacity and reduced sensitivity to entry inhibitors during severe immunodeficiency. J Gen Virol (2005) 1.16
Predictive markers of AIDS dementia complex: CD4 cell count and cerebrospinal fluid concentrations of beta 2-microglobulin and neopterin. J Infect Dis (1996) 1.15
Cerebrospinal fluid neopterin in human immunodeficiency virus type 1 infection. Ann Neurol (1990) 1.14
gp120 induces cell death in human neuroblastoma cells through the CXCR4 and CCR5 chemokine receptors. J Neurochem (2000) 1.10
Lymphotropic virions affect chemokine receptor-mediated neural signaling and apoptosis: implications for human immunodeficiency virus type 1-associated dementia. J Virol (1999) 1.10
Neopterin concentrations in cerebrospinal fluid and serum of individuals infected with HIV-1. AIDS (1989) 1.08
Measuring the "viral load" in cerebrospinal fluid in human immunodeficiency virus infection: window into brain infection? Ann Neurol (1997) 1.06
HIV-1 chemokine coreceptor utilization in paired cerebrospinal fluid and plasma samples: a survey of subjects with viremia. J Infect Dis (2005) 1.04
Primary HIV-1 R5 isolates from end-stage disease display enhanced viral fitness in parallel with increased gp120 net charge. Virology (2008) 1.04
Biological characterization of paired human immunodeficiency virus type 1 isolates from blood and cerebrospinal fluid. Virology (1989) 1.04
Coreceptor usage and RANTES sensitivity of non-syncytium-inducing HIV-1 isolates obtained from patients with AIDS. J Hum Virol (2000) 1.02
HIV biological variability unveiled: frequent isolations and chimeric receptors reveal unprecedented variation of coreceptor use. AIDS (2003) 1.00
Neurological disorders during HIV-1 infection correlate with viral load in cerebrospinal fluid but not with virus phenotype. AIDS (1998) 0.98
AIDS encephalopathy. Neurol Clin (1986) 0.93
Elevated neopterin and beta 2-microglobulin levels in blood and cerebrospinal fluid occur early in HIV-1 infection. AIDS (1989) 0.91
Inhibitory effects of small-molecule CCR5 antagonists on human immunodeficiency virus type 1 envelope-mediated membrane fusion and viral replication. Antimicrob Agents Chemother (2001) 0.90
HIV isolation from cerebrospinal fluid in relation to immunological deficiency and neurological symptoms. AIDS (1988) 0.86
Molecular mapping of epitopes for interaction of HIV-1 as well as natural ligands with the chemokine receptors, CCR5 and CXCR4. AIDS (2003) 0.83
Isolation of human immunodeficiency virus-type 1 (HIV-1) clones with biological and molecular properties of the primary isolate. Virology (2006) 0.79
Molecular mapping of epitopes involved in ligand activation of the human receptor for the neuropeptide, VIP, based on hybrids with the human secretin receptor. J Mol Neurosci (1998) 0.77
Higher HIV-1 RNA cutoff level required in cerebrospinal fluid than in blood to predict positive HIV-1 isolation. J Med Virol (2000) 0.76
Transposable elements in mammals promote regulatory variation and diversification of genes with specialized functions. Trends Genet (2003) 3.49
HIV-1 viral escape in cerebrospinal fluid of subjects on suppressive antiretroviral treatment. J Infect Dis (2010) 3.46
Inhibition of HIV-1 disease progression by contemporaneous HIV-2 infection. N Engl J Med (2012) 2.81
Tuberculosis and HIV co-infection. PLoS Pathog (2012) 2.57
Identification of a free fatty acid receptor, FFA2R, expressed on leukocytes and activated by short-chain fatty acids. Biochem Biophys Res Commun (2003) 2.52
Quality of life and cost-effectiveness of a 3-year trial of lifestyle intervention in primary health care. Arch Intern Med (2010) 2.42
Deletion of the G protein-coupled receptor 30 impairs glucose tolerance, reduces bone growth, increases blood pressure, and eliminates estradiol-stimulated insulin release in female mice. Endocrinology (2008) 2.09
A human cell surface receptor activated by free fatty acids and thiazolidinedione drugs. Biochem Biophys Res Commun (2003) 2.03
Immune activation of the central nervous system is still present after >4 years of effective highly active antiretroviral therapy. J Infect Dis (2007) 1.92
T-bet-dependent expression of osteopontin contributes to T cell polarization. Proc Natl Acad Sci U S A (2005) 1.83
Lysophosphatidic acid binds to and activates GPR92, a G protein-coupled receptor highly expressed in gastrointestinal lymphocytes. J Pharmacol Exp Ther (2006) 1.78
Genomic deletions and precise removal of transposable elements mediated by short identical DNA segments in primates. Genome Res (2005) 1.68
Central nervous system immune activation characterizes primary human immunodeficiency virus 1 infection even in participants with minimal cerebrospinal fluid viral burden. J Infect Dis (2011) 1.59
An endogenous retroviral long terminal repeat is the dominant promoter for human beta1,3-galactosyltransferase 5 in the colon. Proc Natl Acad Sci U S A (2003) 1.56
Cerebrospinal fluid neopterin is brain-derived and not associated with blood-CSF barrier dysfunction in non-inflammatory affective and schizophrenic spectrum disorders. J Psychiatr Res (2013) 1.50
Cerebrospinal fluid interferon-gamma-inducible protein 10 (IP-10, CXCL10) in HIV-1 infection. J Neuroimmunol (2005) 1.49
The non-coding RNA of the multidrug resistance-linked vault particle encodes multiple regulatory small RNAs. Nat Cell Biol (2009) 1.48
Increased survival among HIV-1 and HIV-2 dual-infected individuals compared to HIV-1 single-infected individuals. AIDS (2014) 1.47
Persistent intrathecal immune activation in HIV-1-infected individuals on antiretroviral therapy. J Acquir Immune Defic Syndr (2008) 1.47
The antibody response to pandemic H1N1 2009 influenza vaccine in adult organ transplant patients. Transpl Int (2011) 1.43
The Opitz syndrome gene Mid1 is transcribed from a human endogenous retroviral promoter. Mol Biol Evol (2002) 1.42
Cerebrospinal fluid and neuroimaging biomarker abnormalities suggest early neurological injury in a subset of individuals during primary HIV infection. J Infect Dis (2013) 1.42
Osseointegrated titanium implants for limb prostheses attachments: infectious complications. Clin Orthop Relat Res (2010) 1.42
Microbial translocation correlates with the severity of both HIV-1 and HIV-2 infections. J Infect Dis (2010) 1.40
Multiple effects govern endogenous retrovirus survival patterns in human gene introns. Genome Biol (2006) 1.37
Elevated cerebrospinal fluid neurofilament light protein concentrations predict the development of AIDS dementia complex. J Infect Dis (2007) 1.36
Amyloid and tau cerebrospinal fluid biomarkers in HIV infection. BMC Neurol (2009) 1.32
Cerebrospinal fluid HIV-1 infection usually responds well to antiretroviral treatment. Antivir Ther (2005) 1.28
COPD and the risk of tuberculosis--a population-based cohort study. PLoS One (2010) 1.27
Frequent CXCR4 tropism of HIV-1 subtype A and CRF02_AG during late-stage disease--indication of an evolving epidemic in West Africa. Retrovirology (2010) 1.25
Defining and evaluating HIV-related neurodegenerative disease and its treatment targets: a combinatorial approach to use of cerebrospinal fluid molecular biomarkers. J Neuroimmune Pharmacol (2006) 1.24
Liver-selective glucocorticoid antagonists: a novel treatment for type 2 diabetes. J Med Chem (2004) 1.24
Low prevalence of transmitted drug resistance in patients newly diagnosed with HIV-1 infection in Sweden 2003-2010. PLoS One (2012) 1.24
CSF neurofilament protein (NFL) -- a marker of active HIV-related neurodegeneration. J Neurol (2007) 1.22
Coevolution of RANTES sensitivity and mode of CCR5 receptor use by human immunodeficiency virus type 1 of the R5 phenotype. J Virol (2004) 1.17
Selection of human immunodeficiency virus type 1 R5 variants with augmented replicative capacity and reduced sensitivity to entry inhibitors during severe immunodeficiency. J Gen Virol (2005) 1.16
Treatment intensification has no effect on the HIV-1 central nervous system infection in patients on suppressive antiretroviral therapy. J Acquir Immune Defic Syndr (2010) 1.15
The apical stem-loop of the hepatitis B virus encapsidation signal folds into a stable tri-loop with two underlying pyrimidine bulges. Nucleic Acids Res (2002) 1.08
Raltegravir cerebrospinal fluid concentrations in HIV-1 infection. PLoS One (2009) 1.08
Effect of HIV-2 infection on HIV-1 disease progression and mortality. AIDS (2014) 1.08
Cerebrospinal fluid and plasma HIV-1 RNA levels and lopinavir concentrations following lopinavir/ritonavir regimen. Scand J Infect Dis (2004) 1.06
Evolution of human immunodeficiency virus type 2 coreceptor usage, autologous neutralization, envelope sequence and glycosylation. J Gen Virol (2005) 1.06
Medication report reduces number of medication errors when elderly patients are discharged from hospital. Pharm World Sci (2007) 1.05
[In Process Citation]. Lakartidningen (2015) 1.05
HIV-1 molecular epidemiology in Guinea-Bissau, West Africa: origin, demography and migrations. PLoS One (2011) 1.05
Solution structure of the apical stem-loop of the human hepatitis B virus encapsidation signal. Nucleic Acids Res (2006) 1.04
Continuing intrathecal immunoactivation despite two years of effective antiretroviral therapy against HIV-1 infection. AIDS (2002) 1.04
Darunavir concentrations in cerebrospinal fluid and blood in HIV-1-infected individuals. AIDS Res Hum Retroviruses (2009) 1.04
Primary HIV-1 R5 isolates from end-stage disease display enhanced viral fitness in parallel with increased gp120 net charge. Virology (2008) 1.04
An example of genetically distinct HIV type 1 variants in cerebrospinal fluid and plasma during suppressive therapy. J Infect Dis (2013) 1.03
Treatment of HIV infection: Swedish recommendations 2009. Scand J Infect Dis (2009) 1.03
Cerebrospinal fluid signs of neuronal damage after antiretroviral treatment interruption in HIV-1 infection. AIDS Res Ther (2005) 1.02
Differences in molecular evolution between switch (R5 to R5X4/X4-tropic) and non-switch (R5-tropic only) HIV-1 populations during infection. Infect Genet Evol (2009) 1.01
HIV biological variability unveiled: frequent isolations and chimeric receptors reveal unprecedented variation of coreceptor use. AIDS (2003) 1.00
Cerebrospinal fluid Alzheimer's biomarker profiles in CNS infections. J Neurol (2012) 0.99
Children born to HIV-1-infected women in Sweden in 1982-2003: trends in epidemiology and vertical transmission. J Acquir Immune Defic Syndr (2006) 0.99
Mechanisms of leukotriene B4--triggered monocyte adhesion. Arterioscler Thromb Vasc Biol (2003) 0.99
International network for comparison of HIV neutralization assays: the NeutNet report II. PLoS One (2012) 0.99
Approach to cerebrospinal fluid (CSF) biomarker discovery and evaluation in HIV infection. J Neuroimmune Pharmacol (2013) 0.98
Progress in methodology. Improved reporter gene assays used to identify ligands acting on orphan seven-transmembrane receptors. Pharmacol Toxicol (2003) 0.98
Intravenous ceftriaxone compared with oral doxycycline for the treatment of Lyme neuroborreliosis. Scand J Infect Dis (2005) 0.98
Copy number variation of the gene NCF1 is associated with rheumatoid arthritis. Antioxid Redox Signal (2011) 0.98
Expression pattern analysis of transcribed HERV sequences is complicated by ex vivo recombination. Retrovirology (2007) 0.98
Up-regulation and increased phosphorylation of protein kinase C (PKC) delta, mu and theta in the degenerating rd1 mouse retina. Mol Cell Neurosci (2006) 0.97
Cerebrospinal fluid viral loads reach less than 2 copies/ml in HIV-1-infected patients with effective antiretroviral therapy. Antivir Ther (2006) 0.97
Human endogenous retrovirus family HERV-K(HML-5): status, evolution, and reconstruction of an ancient betaretrovirus in the human genome. J Virol (2004) 0.96
Increase of β-lactam-resistant invasive Haemophilus influenzae in Sweden, 1997 to 2010. Antimicrob Agents Chemother (2012) 0.95
Cerebrospinal fluid neopterin decay characteristics after initiation of antiretroviral therapy. J Neuroinflammation (2013) 0.95
pol gene sequence variation in Swedish HIV-2 patients failing antiretroviral therapy. AIDS Res Hum Retroviruses (2003) 0.95
Frequent intrapatient recombination between human immunodeficiency virus type 1 R5 and X4 envelopes: implications for coreceptor switch. J Virol (2007) 0.95
Quantitative assessment of the antiviral potencies of 21 shRNA vectors targeting conserved, including structured, hepatitis B virus sites. J Hepatol (2010) 0.94
Acute psychotic symptoms in HIV-1 infected patients are associated with increased levels of kynurenic acid in cerebrospinal fluid. Brain Behav Immun (2006) 0.93
Monoclonal antibodies and human sera directed to the secreted glycoprotein G of herpes simplex virus type 2 recognize type-specific antigenic determinants. J Gen Virol (2002) 0.93